Rockwell Medical Sees Q4 Gross Margin Rise to 22%
Sees Q4 gross margin 22%, up from 14% in Q3. Sees Q4 cash flow from operations $2.3M, which represents the second cash flow positive quarter in 2025. As a result, cash and cash equivalents and investments available-for-sale at December 31, 2025 are expected to increase to approximately $25M. "Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, CEO. "We saw a considerable increase in revenue, were cash flow positive, were Adjusted EBITDA positive, and we improved our cash position. Additionally, we continued to improve on our operational efficiencies and reduce expenses, which resulted in a gross margin of 22% in Q4, representing a notable improvement over every quarter in 2025. As we look to 2026, we are focused on three main areas: revenue growth, increased profitability, and portfolio diversification."
Trade with 70% Backtested Accuracy
Analyst Views on RKDA
About RKDA
About the author

Arcadia Biosciences (RKDA) Terminates Agreement with Roosevelt Resources, Resumes Strategic Evaluation
- Termination of Agreement: Arcadia Biosciences announced the termination of its Securities Exchange Agreement with Roosevelt Resources, which previously aimed for a business combination, potentially impacting the company's strategic direction and market confidence.
- Asset Evaluation: Arcadia retains approximately 2.7 million shares of Above Food Ingredients Inc. common stock and believes it is entitled to additional compensation related to the May 2024 sale of GoodWheatTM, indicating potential in asset management.
- Operational Optimization: Over the past two and a half years, Arcadia has streamlined operations and significantly reduced operating expenses, successfully growing the Zola coconut water brand, demonstrating resilience and adaptability in market competition.
- Stock Price Surge: In pre-market trading, RKDA shares rose by 8.96% to $3.31, reflecting investor optimism regarding the company's future strategic adjustments.

Arcadia Biosciences Terminates Agreement with Roosevelt Resources, Resumes Strategic Evaluation
- Agreement Termination: Arcadia Biosciences received a notice on December 24, 2025, from Roosevelt Resources terminating the Securities Exchange Agreement dated December 4, 2024, which prevents the planned business combination, potentially impacting the company's strategic direction.
- Strategic Evaluation Resumption: CEO T.J. Schaefer stated that the company will resume evaluating strategic alternatives to create shareholder value, indicating a search for new growth opportunities amid the ongoing success of its Zola coconut water brand.
- Asset Holdings: Arcadia currently owns approximately 2.7 million shares of Above Food Ingredients Inc. and believes it is entitled to additional compensation related to the May 2024 sale of GoodWheatTM, which could support future strategic transactions.
- Financial Challenges: The company faces funding needs and may require additional equity or debt financing to support future operations; if adequate funding is not secured, it may need to reduce or suspend activities, potentially leading to bankruptcy risks that could adversely affect its financial condition.






